The promises of Treg and Interleukin-2 therapies

for autoimmune and inflammatory diseases, allergy, transplantation & cancer

IL-2 2026 PARIS

Centre International de Conférences Sorbonne Université
October 21-24, 2026

International Organizing Committee

Abul Abbas, Christophe Benoist, Jeff Bluestone, Laurie Dempsey, David Klatzmann (Chair), Thomas Malek, Qizhi Tang, Shimon Sakaguchi, Georges Tsokos, Lucy Walker

Local Organizing Committee

Caroline Aheng, Encarnita Mariotti-Ferrandiz, Michelle Rosenzwajg, Nicolas Tchitchek

Current list of confirmed invited speakers

Abul Abbas; Ammar Al Chalabi; Christophe Benoist, Christoph Binder; Marina Cavazzana; Jens Humrich; Ron Germain; Wolfgang Kastenmueller; David Klatzmann; Vijay Kuchroo; Nigel Leigh; Zhanguo Li; Wan-Lin Lo; Ziad Mallat; Tom Malek; Adel Nada; Sacha Rudensky; Naomi Taylor; George Tsokos; Serena Zacchigna; Jonathan Zalevsky; David Zemmour

Sponsors

NEKTAR ILTOO PHARMA TIIT egle Tx

Funded by the European Union

Partners

ARDIVI Immunologie · Virus · Immunothérapie

Inserm

SORBONNE UNIVERSITÉ CRÉATEURS DE FUTURS DEPUIS 1257

ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS

Wednesday 21

18.00 - Opening Session

Welcome words: **Abul Abbas**

Keynote lectures
Chair: Abul Abbas

- **Treg 2026 – Alexander Rudensky, Ludwig Center MSK, New York**
- **IL-2 based therapies 2026 – David Klatzmann, Sorbonne University, Paris**

20.00 - Welcome reception

Thursday 22

9.00 Session I - *On mechanistic: Treg development and heterogeneity*
Chair: Lucy Walker

1. **David Zemmour: Treg cosmology in the immgenT datasets**
2. **Wan-Lin Lo: in search of the lost Zap70 signal**

Talks from abstracts

a. **BLIMP1 as a transcriptional rheostat for IL-2 responsiveness in Tregs, autoimmunity and T-cell malignancy - Suyasha Roy**
b. **Trophic functions of uterine-resident Tregs - Encarnita Mariotti-Ferrandiz**

10.30 – 11.00 – Coffee break

11.00 Session II – *Lessons and successes from clinical trials with native IL-2*
Chair: George Tsokos

3. **Zhanguo Li: Ld-IL2 treatment of autoimmune diseases in China: from trials to clinical application**
4. **Jonathan Zalevsky: Update on the Clinical Development of Rezpegaldesleukin- Results from Phase 2 Trials in Atopic Dermatitis and Alopecia Areata**
5. **Ziad Mallat: Targeting Tregs with IL-2 in patients with atherosclerotic cardiovascular disease**

Talks from abstracts

a. **Low-dose interleukin-2 for recurrent early pregnancy loss - Michelle Rosenzwajg**
b. **IL-2 in type one diabetes: lessons from the DIABIL-2 and DIAREP trials - Chloe Amouyal**

13.00 – 14.00 – Lunch

14.00 Session III - *On mechanistic: activation and metabolism*
Chair: Vijay Kuchroo

6. **Wolfgang Kastenmueller: The spatial biology of IL-2 reveals a new framework for CD8 T Cell fate decisions**
7. **Tom Malek: Co-targeting the CD40L pathway potentiates Treg-selective IL-2-driven therapy**
8. **George Tsokos: Treg cell metabolism in SLE**

Talks from abstracts

c. **Stability and function of Foxp3 Tregs at steady state and in inflammatory conditions. Benoit Salomon**
d. **Altered activation of Tregs by muteins - Nicolas Tchitchek**

16.00 – 16.30– Coffee break

16.30 Session IV – *CNS and the control of inflammation*
Chair: Christophe Benoist

9. **Vijay Kuchroo: Regulation of Neuroimmune Interactions and Neuroinflammation**
10. **Nigel Leigh: IL-2 in Amyotrophic Lateral Sclerosis IL-2**
11. **Pierre Ellul: IL-2 in autism spectrum disorders**
12. **Marion Leboyer: IL-2 in depression**

18.30 End of the day

20.00 speaker dinner

Friday 23

9.00 Session V - *IL-2 in cardiovascular diseases (session sponsored by the TiilT EU research grant)*
Chair: Ziad Mallat

13. **Christof Binder: on Treg, OSE and inflammatory CVD**
14. **Thomas Vazquez: OSE-targeted IL-2**
15. **Serena Zacchigna: IL-2 and cardiac infarction recovery**
16. **Jens Humrich: IL-2 and cardiovascular SLE**

10.30 – 11.00 - Coffee break

11.00 - Session VI - *Treg cell therapies*
Chair: Olivier Boyer

1. **Naomi Taylor: Engineering TCR fuzzy logic in CAR T cells: implications for Tregs**
2. **Marina Cavazzana-Calvo: FoxP3-transduced CD4 T cells for IPEX**
3. **Marc Martinez-Llordella: Clinical use of engineered Tregs for the induction of tolerance in Autoimmunity and Transplantation**

Talks from abstracts

e. **Autoregulated inflammation-activated IL-2 self-sufficient Tregs: Janie Robert**
f. **Engineering Regulatory T Cells with Chimeric Allergen Receptors for the Treatment of Allergies: Yannick Muller**
g. **Generation of functionally stable iTreg cells for controlling GvHD - Ryoji Kawakami**
h. ***Ex vivo* Expandable Human αβ Double-Negative T Cells Exhibit Regulatory Features and Suppressive Activity: Goeun Jun**

13.30 - 14.30 - Lunch

14.30- Session VII – *on Treg antigen specificities*
Chair: Encarnita Mariotti-Ferrandiz

4. **Ron Germain: Probing Immunity at the Single Cell Level in Tissues Using Highly Multiplex 2D and 3D Imaging**
5. **Christophe Benoist: Regulating the regulators**

Talks from abstracts

i. **Ecology of Treg TCR specificities in humans - Helene Vantomme**
j. **Not all Treg TCRs are equal - Maria De Temple**
k. **in silico identification of TCR specificities - Céline Albalaa**
l. **Epithelial MHC II antigen presentation dynamically informs intestinal homeostasis and injury: Vladyslav Holiar**

16.30 - 17.00 – Coffee break

17.00- Session VIII - Engineering IL-2
Chair: David Klatzmann

6. **Alfred Zipelius: PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer**

Talks from abstracts

m. **Immune activation and clinical responses with STK-012, an α/β IL-2 Receptor Biased Partial Agonist plus Pembrolizumab / Chemotherapy in PD-L1 Negative Non-Squamous NSCLC - Martin Oft**

n. **EGL-003, a Treg-biased IL-2 mutein preserving full agonist activity, mobilizes tissue Treg function preclinically and preferentially activates effector/memory skin-homing Tregs in humans - Jonathan Back**

o. **Interleukin-2 engineering: walking a tightrope between functional optimization and biophysical liabilities - Rojas Gertrudis**

p. **Engineering trispecific IL-2 receptor agonistic antibodies through geometry optimization for enhanced Treg targeting: Vanshika Malviya**

q. **Topical IL-2 Delivery to the Hair Follicle via Cutibacterium acnes: A Microbiome-Enabled Treg Activation Strategy for Alopecia Areata: Decrulle Antoine**

18.45 End of the day

Saturday 24

9.00 Session IX- *IL-2/Treg and the pathophysiology of autoimmune diseases*

Chair: Jens Humrich

r. **Interferon-stimulated gene signature predicts clinical response to low-dose IL-2 in autoimmune diseases - Nicolas Tchitchek**

s. **A Treg TCR signature of low-dose IL-2 treatment in humans - Martin Pezous**

t. **Induced regulatory T cells from patients with primary biliary cholangitis are suppressive and stable and are different from natural regulatory T cells - Irune Lasa Elosegi**

u. **Tregs in rheumatology - Marie Binvignat**

v. **Dysregulation of the Treg-IL-2 axis in inflammatory myopathies: from pathophysiology to targeted intervention- Jens Humrich**

w. **Computational solution for the analysis of flow cytometry samples in SMART - a multi-center longitudinal clinical study in type 1 diabetes. Astrid Fabri**

10.30 – 11.00 – Coffee break

11.00 Session X – *IL-2 and Tregs: the pharma perspective*

Chair: Abul Abbas

7. **Christie Fanton /Nektar: Pegylated IL-2**
8. **William Hariri/ILTOO: IL-2 in neuroinflammatory diseases**
9. **Adel Nada/Trutina: The future of Treg cell therapies**

Round Table: What ‘s next?

13.00 End of the meeting